drugset / Trial / NCT02740166

Preventing Recurrent Bleeding After Eradication of Esophageal Varices

NCT02740166 ↗

Phase 4 Unknown 212 enrolled Kaohsiung Veterans General Hospital.
RandomizedParallel-groupOpen-labelTreatment

Summary

Esophageal variceal bleeding is a severe complication of portal hypertension. Banding ligation plus non-selective beta-blockers is the current recommendation for prevention of recurrent bleeding. However, the optimal duration of use of non-selective beta-blockers is not well defined. This study aims at comparing the rebleeding rate and adverse effects in patients using or without using propranolol after eradication of esophageal varices.

Timeline

Start
2013-06
Primary completion
2018-01
Completion
—

Outcome

Met primary endpoint

paper The upper 95% CI bound of the difference was within the margin of 13.2%, and the noninferiority of group A to group B was established. PMID 37543755 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 30 mg —

Indications